{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:46:12Z","timestamp":1793317572088,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ejpb.2023.04.009","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T11:38:00Z","timestamp":1681731480000},"page":"141-155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Improvement and characterization of oral absorption behavior of clofazimine by SNEDDS: Quantitative evaluation of extensive lymphatic transport"],"prefix":"10.1016","volume":"187","author":[{"given":"Keita","family":"Yamanouchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Ishimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kakuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Kawatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Higaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2023.04.009_b0005","first-page":"6","article-title":"B663 in the treatment of leprosy. Preliminary report of a pilot trial","volume":"33","author":"Browne","year":"1962","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.ejpb.2023.04.009_b0010","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3390\/antibiotics11060806","article-title":"Adapting clofazimine for treatment of cutaneous tuberculosis by using self-double-emulsifying drug delivery system","volume":"11","author":"van Staden","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.ejpb.2023.04.009_b0015","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkr444","article-title":"Clofazimine: current status and future prospects","volume":"67","author":"Colo","year":"2012","journal-title":"J. Antimicorb. Chemother."},{"key":"10.1016\/j.ejpb.2023.04.009_b0020","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1164\/rccm.201803-0497ED","article-title":"Drug-resistant tuberculosis in Europe. What are we waiting for?","volume":"198","author":"Monedero-Recuero","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejpb.2023.04.009_b0025","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/cid\/cix561","article-title":"Epidemiology of pediatric multidrug-resistant tuberculosis in the United States, 1993\u20132014","volume":"65","author":"Smith","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejpb.2023.04.009_b0030","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/jac\/43.5.615","article-title":"Antimycobacterial activities of riminophenazines","volume":"43","author":"Reddy","year":"1999","journal-title":"J. Antimicrob. CHemother."},{"key":"10.1016\/j.ejpb.2023.04.009_b0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000007255","article-title":"In vitro investigation of the antimicrobial activities of novel tetramethylpiperidine-substituted phenazines against Mycobacterium tuberculosis","volume":"46","author":"van Rensburg","year":"2000","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ejpb.2023.04.009_b0040","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijid.2016.12.015","article-title":"Improving access to tuberculosis preventive therapy and treatment for children","volume":"56","author":"Marais","year":"2017","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ejpb.2023.04.009_b0045","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3109\/03602539508994208","article-title":"The pharmacology, metabolism and chemistry of clofazimine","volume":"27","author":"O\u2019Connor","year":"1995","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.ejpb.2023.04.009_b0050","doi-asserted-by":"crossref","first-page":"e0005373","DOI":"10.1371\/journal.pntd.0005373","article-title":"A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis","volume":"11","author":"Love","year":"2017","journal-title":"PLos Negl. Trop. Dis."},{"key":"10.1016\/j.ejpb.2023.04.009_b0055","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41586-021-03431-4","article-title":"Clofazimine broadly inhibits coronaviruses including SARS-CoV-2","volume":"593","author":"Yuan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2023.04.009_b0060","unstructured":"Novartis. Lamprene\u00ae Prescribing Information; NDA 19-500\/S-010; Novartis: East Hanover, NJ, USA, 2002. https:\/\/www.accessdata.fda.gov\/ drugsatfda_docs\/label\/2003\/19500slr010_lamprene_lbl.pdf (accessed on 18 August 2022)."},{"key":"10.1016\/j.ejpb.2023.04.009_b0065","first-page":"9","article-title":"Pharmacokinetics of clofazimine in healthy volunteers","volume":"55","author":"Z. S.-Lanyi, W. Dieterle, J.P. Dubois, W. Theobald, W. Vischer","year":"1987","journal-title":"Int. J. Lepr. Other Mycobact. Dis."},{"key":"10.1016\/j.ejpb.2023.04.009_b0070","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tube.2004.04.001","article-title":"Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid","volume":"84","author":"Nix","year":"2004","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ejpb.2023.04.009_b0075","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1081\/DDC-120006431","article-title":"Evaluation of solid dispersions of clofazimine","volume":"28","author":"Narang","year":"2002","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2023.04.009_b0080","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jac\/33.2.273","article-title":"Bioavailability and chemotherapeutic activity of clofazimine against Mycobacterium avium complex infections in beige mice following a single implant of a biodegradable polymer","volume":"33","author":"Kailasam","year":"1994","journal-title":"J Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2023.04.009_b0085","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1128\/AAC.43.7.1638","article-title":"Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine","volume":"43","author":"Adams","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2023.04.009_b0090","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejps.2017.11.004","article-title":"Development of PLGA nanoparticles loaded with clofazimine for oral delivery: assessment of formulation variables and intestinal permeability","volume":"112","author":"Chaves","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.04.009_b0095","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/03639045.2021.1892743","article-title":"Nanostructured lipid carrier-mediated lung targeted drug delivery system to enhance the safety and bioavailability of clofazimine","volume":"47","author":"Patil","year":"2021","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2023.04.009_b0100","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.biopha.2004.02.001","article-title":"Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs","volume":"58","author":"Gursoy","year":"2004","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejpb.2023.04.009_b0105","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/j.ddtec.2012.03.002","article-title":"Lipid-based formulations for oral delivery of lipophilic drugs","volume":"9","author":"Kuentz","year":"2012","journal-title":"Drug Discovery Today Technol."},{"key":"10.1016\/j.ejpb.2023.04.009_b0110","first-page":"32","article-title":"Self-microemulsifying DDS formulation (in Japanese)","volume":"70","author":"Higaki","year":"2010","journal-title":"J. Pharm. Sci. Technol. Japan"},{"key":"10.1016\/j.ejpb.2023.04.009_b0115","first-page":"2595","article-title":"Improvement of oral bioavailability of N-251, a novel antimalarial drug, by increasing lymphatic transport with long-chain fatty acid-based self-nanoemulsifying drug delivery system","volume":"32","author":"Imada","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2023.04.009_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105721","article-title":"Improvement of lipid solubility and oral bioavailability of a poorly water-soluble and poorly lipid-soluble drug, rebamipide, by utilizing its counter ion and SNEDDS preparation","volume":"159","author":"Okawa","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.04.009_b0125","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ejpb.2022.02.002","article-title":"Extensive improvement of oral bioavailability of mebendazole, a brick dust, by polymer-containing SNEDDS preparation: disruption of high crystallinity by utilizing its counter ion","volume":"172","author":"Sumimoto","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2023.04.009_b0130","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s11095-021-03144-3","article-title":"Clofazimine-loaded mucoadhesive nanoparticles prepared by flash nanoprecipitation for strategic intestinal delivery","volume":"38","author":"Yamada","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2023.04.009_b0135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijpharm.2012.06.032","article-title":"Characterization and evalulation of self-microemulsifying drug delivery systems with porous carriers as systems for improved carbamazepine release","volume":"436","author":"Milovi\u0107","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.04.009_b0140","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ejpb.2012.10.007","article-title":"Development and characterization of a self-microemulsifying drug delivery systems (SMEDDSs) for the vaginal administration of antiretroviral UC-781","volume":"83","author":"McConville","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2023.04.009_b0145","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1007\/s11095-010-0309-1","article-title":"Nano-emulsions and micro-emulsions: classifications of the critical differences","volume":"28","author":"Anton","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2023.04.009_b0150","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1211\/jpp.60.1.0008","article-title":"Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments","volume":"60","author":"McConnell","year":"2008","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2023.04.009_b0155","unstructured":"Food and Drug Administration (FDA). Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers 2005. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers."},{"key":"10.1016\/j.ejpb.2023.04.009_b0160","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0090-9556(25)08574-5","article-title":"Stereoelective dispostion of S-8666, a novel uricosuric antihyper-tensive diuretic, and its N-monodemethylated metabolite in a perfused rat liver preparation: effect of protein binding on the kinetics of S-8666","volume":"20","author":"Higaki","year":"1992","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejpb.2023.04.009_b0165","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/00498250310001615771","article-title":"Pharmacokinetic analysis of factors determining elimination pathways for sulfate and glucuronide Metabolites of xenobiotics II: studies with isolated perfused rat liver","volume":"33","author":"Higaki","year":"2003","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejpb.2023.04.009_b0170","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2133\/dmpk.19.198","article-title":"Regulation of drug absorption from small intestine by enteric nervous system I: a poorly absorbable drug via passive diffusion","volume":"19","author":"Higaki","year":"2004","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2023.04.009_b0175","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.xphs.2021.09.014","article-title":"Possible regulation of P-glycoprotein function by adrenergic agonists in a vascular-luminal perfused preparation of small intestine","volume":"110","author":"Mukai","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.04.009_b0180","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1152\/ajplegacy.1970.218.1.197","article-title":"Vascular perfusion of isolated rat gut: norepinephrine and glucocorticoid requirement","volume":"218","author":"Windmueller","year":"1970","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejpb.2023.04.009_b0185","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1152\/ajplegacy.1961.200.6.1315","article-title":"Effect of insulin on potassium transfer in isolated rat liver","volume":"200","author":"Mortimore","year":"1961","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejpb.2023.04.009_b0190","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000136003","article-title":"A versatile method for the in vitro perfusion of isolated organs of rats and mice with particular reference to liver","volume":"2","author":"Kv\u011btina","year":"1961","journal-title":"Pharmacol."},{"key":"10.1016\/j.ejpb.2023.04.009_b0195","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/bdd.2510160502","article-title":"Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals","volume":"16","author":"Kararli","year":"1995","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejpb.2023.04.009_b0200","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jconrel.2007.03.002","article-title":"Prediction of oral absorption of griseofulvin, a BCS class II drug, based on GITA model: utilization of a more suitable medium for in-vitro dissolution study","volume":"119","author":"Fujioka","year":"2007","journal-title":"J. Controlled Rel."},{"key":"10.1016\/j.ejpb.2023.04.009_b0205","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1248\/bpb1978.4.879","article-title":"A pharmacokinetic analysis program (MULTI) for microcomputer","volume":"4","author":"Yamaoka","year":"1981","journal-title":"J. Pharmacobio-Dyn."},{"key":"10.1016\/j.ejpb.2023.04.009_b0210","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.addr.2016.02.005","article-title":"Computational prediction of formulation strategies for beyond-rule-of-5 compounds","volume":"101","author":"Bergstr\u00f6m","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2023.04.009_b0215","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/A:1018922517162","article-title":"Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation","volume":"11","author":"Mueler","year":"1994","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2023.04.009_b0220","doi-asserted-by":"crossref","first-page":"9179","DOI":"10.1073\/pnas.1201627109","article-title":"Castor oil induces laxation and uterus contraction via ricinoleic acid activating prostaglandin EP3 receptors","volume":"109","author":"Tunaru","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejpb.2023.04.009_b0225","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5768805","article-title":"Antidiarrheal and antisecretory effect of 80% hydromethanolic leal extract of Moringa stenopetala baker f. in mice","author":"Woldeyohannes","year":"2022","journal-title":"Biochem. Res. Int."},{"key":"10.1016\/j.ejpb.2023.04.009_b0230","series-title":"Surfactant systems: Their Chemistry, Pharmacy and Biology","first-page":"469","article-title":"Emulsion","author":"Attwood","year":"1983"},{"key":"10.1016\/j.ejpb.2023.04.009_b0235","article-title":"A review of in vitro drug release test methods for nano-sized dosage forms","volume":"2014","author":"D\u2019Souza","year":"2014","journal-title":"Adv. Pharm."},{"key":"10.1016\/j.ejpb.2023.04.009_b0240","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1021\/acs.molpharmaceut.8b00699","article-title":"Impact of drug physicochemical properties on lipolysis-triggered drug supersaturation and precipitation from lipid-based formulations","volume":"15","author":"Alsk\u00e4r","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2023.04.009_b0245","series-title":"Recent Progress in Physicochemical Characterization and Formulation Technologies for Poorly Soluble Drugs","first-page":"151","article-title":"Self-emulsifying drug delivery system (in Japanese)","author":"Higaki","year":"2010"},{"key":"10.1016\/j.ejpb.2023.04.009_b0250","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0378-5173(86)90027-X","article-title":"Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules","volume":"34","author":"Charman","year":"1986","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.04.009_b0255","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.addr.2007.10.014","article-title":"Enhancing intestinal drug solubilisation using lipid-based delivery systems","volume":"60","author":"Porter","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2023.04.009_b0260","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ejps.2004.12.006","article-title":"Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs","volume":"24","author":"Dahan","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.04.009_b0265","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejps.2008.07.003","article-title":"Intestinal lymphatic transport of halofantrine in rats assessed using a chylomicron flow blocking approach: the influence of polysorbate 60 and 80","volume":"35","author":"Lind","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.04.009_b0270","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.apsb.2017.02.002","article-title":"Self-microemulsifying drug delivery system for improving the bioavailability of huperzine A by lymphatic uptake","volume":"7","author":"Li","year":"2017","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.ejpb.2023.04.009_b0275","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/bdd.2510110908","article-title":"Absorption of a pharmacological dose of vitamin D3 from two different lipid vehicles in man: comparison of peanut oil and a medium chain triglyceride","volume":"11","author":"Holmberg","year":"1990","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejpb.2023.04.009_b0280","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0378-5173(95)04265-2","article-title":"Intestinal lymphatic transport of three retinoids in the rat after oral administration: effect of lipophilicity and lipid vehicle","volume":"130","author":"Nankervis","year":"1996","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.04.009_b0285","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/1520-6017(200008)89:8<1073::AID-JPS12>3.0.CO;2-V","article-title":"Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats","volume":"89","author":"Caliph","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.04.009_b0290","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/jps.21650","article-title":"Supersatrurating drug delivery systems: the answer to solubility-limited oral bioavailability?","volume":"98","author":"Brouwers","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.04.009_b0295","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.addr.2007.09.007","article-title":"Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update","volume":"60","author":"Trevaskis","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2023.04.009_b0300","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.biochi.2013.08.011","article-title":"From fatty-acid sensing to chylomicron synthesis: role of intestinal lipid-binding proteins","volume":"96","author":"Buttet","year":"2014","journal-title":"Biochimie"},{"key":"10.1016\/j.ejpb.2023.04.009_b0305","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s11095-014-1578-x","article-title":"Exploring the impact of drug properties on the extent of intestinal lymphatic transport - in vitro and in vivo studies","volume":"32","author":"Lawless","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2023.04.009_b0310","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s11095-010-0199-2","article-title":"The mechanism of lymphatic access of two cholesteryl ester transfer protein inhibitors (CP524,515 and CP532,623) and evaluation of their impact on lymph lipoprotein profiles","volume":"27","author":"Trevaskis","year":"2010","journal-title":"Pharm. Res."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123000899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123000899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:53:03Z","timestamp":1760547183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641123000899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":62,"alternative-id":["S0939641123000899"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.04.009","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvement and characterization of oral absorption behavior of clofazimine by SNEDDS: Quantitative evaluation of extensive lymphatic transport","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}